article thumbnail

Statement on long-term cardiovascular consequences of maternal hypertension: call for urgent action

Heart BMJ

One in five women suffer from hypertension worldwide, and almost half of the mortality in women is caused by cardiovascular disease (CVD) (WHO). The timely launch of the Women’s Health Strategy for England in 2022 focuses attention on the changing health and needs of women across their life.

article thumbnail

Cardiovascular outcomes in long COVID-19: a systematic review and meta-analysis

Frontiers in Cardiovascular Medicine

Systematic search conducted without language restrictions from December 1, 2019 to June 31, 2022 on PubMed, EMBASE, Web of Science, Cochrane library, ProQuest Coronavirus Research Database, COVID-19 Living Overview of the Evidence (L-OVE) subset of Episteminokos and the World Health Organization (WHO) Covid-19 databases.

article thumbnail

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

DAIC

The BACKBEAT pivotal study will evaluate the efficacy and safety of atrioventricular interval modulation (“AVIM”) therapy (also known as BackBeat CNT), for the treatment of pacemaker-indicated patients with uncontrolled hypertension despite the use of antihypertensive medications. Orchestra BioMed and Medtronic, Inc. Kowal, M.D., and Europe.

Pacemaker 105
article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Risk factors for fluorouracil-induced cardiotoxicity in patients with gastrointestinal tumor

Frontiers in Cardiovascular Medicine

ObjectiveTo explore the risk factors for cardiotoxicity in patients with gastrointestinal (GI) tumors treated with fluorouracil drugs.MethodsThis study included patients with GI tumors who received fluorouracil at our hospital between January 2018 and April 2022. The demographic and clinical characteristics were collected.

article thumbnail

Cardiovascular Disease and Deaths On the Rise

CardiacWire

is at an all time high, with 942k cardiovascular disease-related deaths in 2022, up by 10k from 2021. as of 2020) have some form of CVD (comprising CHD, HF, stroke, and hypertension). Excluding hypertension (CHD, HF, and stroke only), just 9.9% Four years after that goals due date, the burden of CVD in the U.S. adults have CVD.

article thumbnail

Predictors of Outcomes in Mild Pulmonary Hypertension

American College of Cardiology

What is the impact on prognosis of the 2022 ESC/ERS pulmonary hypertension (PH) guidelines on the new redefined hemodynamic threshold for the diagnosis of precapillary PH?